Friday 13 May 2016

Dr Reddys Q4 net dives 86% on Venezuelan write-off and other top pharma news

Pharmaceutical companies Wockhardt and Alembic have challenged in the Delhi High Court the National Pharmaceutical Pricing Authority’s recent moves related to fixation and revision of prices of medicines.

Doctor prescription and medicine
Pharma major Dr Reddy’s Laboratories consolidated net profit plunged 86 per cent at Rs 74.6 crore in the fourth quarter ended March 31, 2016, against Rs 519 crore earned in the corresponding quarter of the previous financial year. The revenue of the Hyderabadbased company declined 3 per cent to Rs 3,756 crore (Rs 3,870 crore).

Pharmaceutical companies Wockhardt and Alembic have challenged in the Delhi High Court the National Pharmaceutical Pricing Authority’s recent moves related to fixation and revision of prices of medicines. 

Six hundred tuberculosis (TB) patients will get access to Bedaquiline drug in India for the first time starting this month. The Union Health Ministry is introducing the drug for patients who have encountered earlier failures in treatment of the infection. Such patients have increasingly gone on to become resistant to basic first line and second line of anti-TB drugs. 

Sun Pharmaceutical Industries said it isn’t aware of any adverse findings related to the manufacturing plants of Ranbaxy Laboratories — which it acquired in 2014 — that are said to be part of an affidavit filed in the Supreme Court by the drug regulator.“ Based on our understanding of the matter, there is no truth to the assertions you are making,” a Sun spokesperson said in an email to ET. Affidavit was submitted by DCGI following a PIL filed by activist-lawyer ML Sharma.

Glenmark Pharma posted over 13-fold jump in consolidated net profit to Rs143.04 crore during January-March quarter, against Rs10.61 crore during the same period last year, on the back of robust sales across all markets, including the US, Europe and India. Consolidated revenue rose to Rs2,306.67 crore against Rs1,775.81 crore last year.

Drugmaker Sanofi has recalled four batches of painkiller medicine Combiflam due to delay in the disintegration time of the tablet. This qualifies as a class-III recall where consumption of the product is not likely to cause adverse health consequences, a company spokesperson said.

1 comment: